COSM icon

Cosmos Holdings

0.3350 USD
-0.0099
2.87%
At close Apr 17, 4:00 PM EDT
After hours
0.3360
+0.0010
0.30%
1 day
-2.87%
5 days
-4.29%
1 month
-33.53%
3 months
-60.93%
6 months
-58.94%
Year to date
-51.17%
1 year
-46.83%
5 years
-99.61%
10 years
-99.61%
 

About: Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.

Employees: 123

0
Funds holding %
of 7,407 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

20% more funds holding

Funds holding: 15 [Q3] → 18 (+3) [Q4]

6.56% less ownership

Funds ownership: 13.52% [Q3] → 6.97% (-6.56%) [Q4]

13% less call options, than puts

Call options by funds: $13K | Put options by funds: $15K

48% less capital invested

Capital invested by funds: $2.1M [Q3] → $1.08M (-$1.02M) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for COSM.

Financial journalist opinion

Based on 3 articles about COSM published over the past 30 days

Neutral
GlobeNewsWire
3 days ago
Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million
CHICAGO, April 16, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Highlights Income Statement: FY 2024 performance was marked by revenue growth, an increase in R&D investments, and a substantial reduction in operating expenses, while bottom-line results were impacted by the absence of non-recurring gains recognized in the prior year.
Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million
Neutral
GlobeNewsWire
1 week ago
Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L
CHICAGO, April 09, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly owned subsidiary, Cana Laboratories (“Cana”), has completed the latest upgrades to its manufacturing capabilities and capacity, and has secured a long-term, five-year contract manufacturing agreement with Pharmex S.A. (“Pharmex”) for the annual production of 300,000 bottles of the antiseptic drug AMBITASOL 1L, totaling 1,500,000 units over the duration of the agreement.
Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L
Neutral
GlobeNewsWire
1 week ago
Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order
CHICAGO, April 08, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the launch of its Sky Premium Life food supplements brand in Albania, in partnership with Pharma Cell , a leading consumer health and medical supplement company that will serve as the distributor in the country. Cosmos Health has secured an initial annual order worth $300,000 and anticipates further scaling its collaboration with Pharma Cell over time.
Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order
Neutral
Accesswire
1 month ago
Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates
CHICAGO, IL / ACCESS Newswire / February 26, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the addition of 60 new Stock Keeping Units (SKUs) to its Sky Premium Life nutraceutical brand. This expansion brings the total SKU count to over 150, broadening the product range to meet growing demand and evolving customer needs.
Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates
Neutral
Accesswire
1 month ago
Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1
CHICAGO, IL / ACCESS Newswire / February 18, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. About Cosmos Health Inc. Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group.
Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1
Neutral
Accesswire
2 months ago
Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market
Finalizing scale-up production phase Engaging with Contract Research Organizations to complete the technical dossier Clinical trials expected to complete in late 2025 or early 2026 Potential classification as a Class III medical device Product launch expected in the first or second quarter of 2026 Further updates on progress to follow in the coming months CHICAGO, IL / ACCESS Newswire / February 11, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it is entering the final stage of development for CCX0722, its innovative weight management solution. The Company is currently finalizing the scale-up production phase, paving the way for human clinical trials and targeting a market launch in the first or second quarter of 2026.
Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market
Neutral
Accesswire
2 months ago
Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market
CHICAGO, IL / ACCESS Newswire / February 10, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the filing of two new patent applications, covering groundbreaking developments in the treatment of glioma, an aggressive brain cancer, and hematologic malignancies, a complex group of blood cancers. The patent application for glioma has been filed under number N2039647, while the second application, numbered N2039645, focuses on hematologic malignancies, including multiple myeloma.
Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market
Neutral
Accesswire
2 months ago
Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations
CHICAGO, IL / ACCESS Newswire / February 10, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Dimitris Moraitis as Vice President of Strategy & Operations. Mr. Moraitis brings over 25 years of experience in strategic planning, operations, and business development within the pharmaceutical sector.
Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations
Neutral
Accesswire
2 months ago
Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility
CHICAGO, IL / ACCESS Newswire / February 7, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly owned subsidiary, Cana Laboratories ("Cana"), has entered into a new long-term ten-year contract manufacturing agreement with Provident Pharmaceuticals ("Provident"), a specialty pharmaceutical company, to produce four pharmaceutical products. These include Miorelique®, BE Union F.C.
Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility
Neutral
Accesswire
2 months ago
Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar
CHICAGO, IL / ACCESS Newswire / February 6, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that it has received an initial purchase order of $578,460 from Al Rabwa International Services and Trading ("Al Rabwa") for its Sky Premium Life® food supplement products in Qatar. The initial purchase order covers 35 of the Company's 79 SKUs.
Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar
Charts implemented using Lightweight Charts™